LEADER 00960nam--2200349---450- 001 990003693310203316 005 20121001132033.0 010 $a978-88-230-1666-8 035 $a000369331 035 $aUSA01000369331 035 $a(ALEPH)000369331USA01 035 $a000369331 100 $a20121001d2012----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $a||||||||001yy 200 1 $aFernando Pessoa$fSimone Celani 210 $aRoma$cEdiesse$d2012 225 2 $aFondamenti$iChi é$v2 410 0$12001$aFondamenti$iChi é$v2 600 1 $aPessoa,$bFernando$2BNCF 676 $a869.141 700 1$aCELANI,$bSimone$0592714 801 0$aIT$bsalbc$gISBD 912 $a990003693310203316 951 $aVI.6.B. 80$b7650 L.G.$cVI.6.B.$d00059057 959 $aBK 969 $aUMA 979 $aPASSARO$b90$c20121001$lUSA01$h1318 979 $aPASSARO$b90$c20121001$lUSA01$h1320 996 $aFernando Pessoa$91142035 997 $aUNISA LEADER 05578nam 2200685 450 001 9910460911303321 005 20200909225244.0 010 $a0-12-803120-4 010 $a0-12-803119-0 035 $a(CKB)3710000000453344 035 $a(EBL)2120151 035 $a(SSID)ssj0001550382 035 $a(PQKBManifestationID)16166286 035 $a(PQKBTitleCode)TC0001550382 035 $a(PQKBWorkID)14810841 035 $a(PQKB)10168438 035 $a(MiAaPQ)EBC2120151 035 $a(PPN)192174479 035 $a(Au-PeEL)EBL2120151 035 $a(CaPaEBR)ebr11083664 035 $a(CaONFJC)MIL822713 035 $a(OCoLC)918625276 035 $a(EXLCZ)993710000000453344 100 $a20150812h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCytochrome P450 function and pharmacological roles in inflammation and cancer /$fedited by James P. Hardwick, S. J. Enna, Lynn Lecount ; contributors, Mohamed A. Abdelmegeed [and thirty-three others] 205 $aFirst edition. 210 1$aAmsterdam, [Netherlands] :$cAcademic Press,$d2015. 210 4$d©2015 215 $a1 online resource (506 p.) 225 1 $aAdvances in Pharmacology,$x1054-3589 ;$vVolume 74 300 $aDescription based upon print version of record. 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aFront Cover; Cytochrome P450 Function and Pharmacological Roles in Inflammation and Cancer; Copyright; Contents; Contributors; Preface; References; Chapter One: Role of Cytochrome P450 Monooxygenase in Carcinogen and Chemotherapeutic Drug Metabolism; 1. Introduction; 2. Historical Aspects of Chemical Carcinogenesis Leading to Discovery of the Cytochrome P450 Monooxygenase; 2.1. Cytochromes P450; 2.2. Butter Yellow Carcinogenesis; 2.3. PAH Carcinogenesis: Protein Adducts and Induction of Metabolism 327 $a3. Cytochrome P450-Monooxygenase-Mediated Activation of Procarcinogen and Chemotherapeutic Prodrugs3.1. Aromatic Azo Compounds; 3.2. Polycyclic Aromatic Hydrocarbons; 3.3. Polychlorinated Biphenyls; 3.3.1. Polychlorinated Biphenyls with Low Chlorine Content; 3.3.2. Highly Chlorinated Biphenyls; 3.4. Vinyl Chloride; 3.5. Nitrosamines; 3.6. Furans; 3.7. Chemotherapeutic Prodrugs; 3.7.1. Cyclophosphamide; 3.7.2. Procarbazine and Other Hydrazine Derivatives; 3.7.3. Anthracycline Antibiotics; 4. Factors That Regulate Changes in Gene Expression: Differences Between Rodents and Humans 327 $a4.1. Hepatic Nuclear Receptors and Enzyme Induction4.2. Differences Between Rodent and Human Receptors; 4.3. CAR Splice Variants and Ligand Specificity; 4.4. Exogenous Compounds Acting on the PPAR; 4.5. Underlying Regulation by Other Hormones and Transcription Factors; 4.6. Effects of Environmental Agents; 5. Polymorphic Cytochrome P450 Variants Impacting Expression and Cancer Susceptibility; 5.1. Cytochrome P4501A1 and Glutathione S-Transferase M1; 5.2. Cytochrome P4502D6 and Cytochrome P4502E1; 6. Conclusion; Conflict of Interest; Acknowledgment; References 327 $aChapter Two: Involvement of Cytochrome P450 in Reactive Oxygen Species Formation and Cancer1. Introduction; 2. Reactive Oxygen Species Formation in Biological Systems; 2.1. Oxygen Reactivity and Formation of Reactive Oxygen Species; 2.2. Types of Reactive Oxygen Species and Their Reactivities; 2.2.1. Superoxide Radical Anion; 2.2.2. Hydrogen Peroxide; 2.2.3. Hydroxyl Radical; 2.2.4. Peroxyl Radical; 2.2.5. Singlet Oxygen; 3. Protective Agents to Combat Reactive Oxygen Species; 3.1. Antioxidants; 3.1.1. Antioxidant Enzymes; 3.1.2. Nonenzymatic Antioxidants; 3.1.2.1. Glutathione 327 $a3.1.2.2. Vitamin E, Vitamin C, and ?-Carotene3.1.2.3. Lycopene; 3.1.2.4. Melatonin; 4. CYP Catalytic Cycle and Involvement of CYP Enzymes in Reactive Oxygen Species Formation; 5. Roles of Reactive Oxygen Species in Cancer; 5.1. Reactive Oxygen Species and Cell Signaling; 6. Relationship Between CYP Enzymes and Cancer; 6.1. CYP Expression in Neoplastic Tissues; 6.2. CYP Polymorphism and Cancer Risk; 6.3. CYP Enzymes and Chemical Carcinogenesis; 6.4. CYP Enzymes and Cancer Therapy; 7. Conclusion; Conflict of Interest; Acknowledgments; References 327 $aChapter Three: Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases 330 $a Cytochrome P450 Function and Pharmacological Roles in Inflammation and Cancer, the latest volume in the Advances in Pharmacology series, presents not only the function of cytochrome P450 but also its pharmacological roles in inflammation and cancer.

410 0$aAdvances in pharmacology (San Diego, Calif.) ;$vVolume 74. 606 $aCytochrome P-450 608 $aElectronic books. 615 0$aCytochrome P-450. 676 $a572.7 702 $aHardwick$b James P. 702 $aEnna$b S. J. 702 $aLecount$b Lynn 702 $aAbdelmegeed$b Mohamed A. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460911303321 996 $aCytochrome P450 function and pharmacological roles in inflammation and cancer$91517911 997 $aUNINA